Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) EBITDA Margin: 2009-2020

Historic EBITDA Margin for Avadel Pharmaceuticals (AVDL) over the last 12 years, with Dec 2020 value amounting to 26.04%.

  • Avadel Pharmaceuticals' EBITDA Margin rose 49790.00% to 431.08% in Q4 2020 from the same period last year, while for Dec 2020 it was 36.88%, marking a year-over-year increase of 7760.00%. This contributed to the annual value of 26.04% for FY2020, which is 6676.00% up from last year.
  • Avadel Pharmaceuticals' EBITDA Margin amounted to 26.04% in FY2020, which was up 163.94% from -40.72% recorded in FY2019.
  • Avadel Pharmaceuticals' EBITDA Margin's 5-year high stood at 51.66% during FY2017, with a 5-year trough of -101.60% in FY2018.
  • Over the past 3 years, Avadel Pharmaceuticals' median EBITDA Margin value was -40.72% (recorded in 2019), while the average stood at -38.76%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first plummeted by 15,327bps in 2018, then skyrocketed by 6,676bps in 2020.
  • Yearly analysis of 5 years shows Avadel Pharmaceuticals' EBITDA Margin stood at -3.30% in 2016, then soared by 5,497bps to 51.66% in 2017, then slumped by 15,327bps to -101.60% in 2018, then skyrocketed by 6,089bps to -40.72% in 2019, then skyrocketed by 6,676bps to 26.04% in 2020.